Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.

Publication

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.

Journal Paper/Review - Nov 20, 2023

Rubbert-Roth Andrea, Kakehasi Adriana M, Takeuchi Tsutomu, Schmalzing Marc, Palac Hannah, Coombs Derek, Liu Jianzhong, Anyanwu Samuel I, Lippe Ralph, Curtis Jeffrey R

Citation

Rubbert-Roth A, Kakehasi A, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu S, Lippe R, Curtis J. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther 2023

Type

Journal Paper/Review (English)

Journal

Rheumatol Ther 2023

Publication Date

Nov 20, 2023

Issn Print

2198-6576

Brief description/objective

This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated with upadacitinib (UPA) or active comparators.